SAN.PA - Sanofi

Paris - Paris Delayed price. Currency in EUR
65.05
+0.16 (+0.25%)
At close: 5:37PM CET
Stock chart is not supported by your current browser
Previous close64.89
Open65.01
Bid71.12 x 1000
Ask71.74 x 44000
Day's range64.42 - 65.22
52-week range25.38 - 87.65
Volume1,434,698
Avg. volume7,722
Market cap80.332B
BetaN/A
PE ratio (TTM)9.69
EPS (TTM)6.71
Earnings date27 Apr 2018
Forward dividend & yield2.96 (4.05%)
Ex-dividend date2017-05-16
1y target est83.00
  • GlobeNewswire19 hours ago

    Sanofi: Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Bioverativ

    Hart-Scott-Rodino waiting period expires for Sanofi`s acquisition of Bioverativ Paris - February 23, 2018 - Sanofi announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements ...

  • Globe Newswire19 hours ago

    Sanofi: Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Bioverativ

    February 23, 2018 - Sanofi announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"), applicable to Sanofi's proposed acquisition of Bioverativ Inc. ("Bioverativ", NASDAQ: BIVV) has expired. On February 7, 2018, Sanofi commenced a tender offer (the "Offer") to purchase all outstanding shares of common stock of Bioverativ (the "Shares") for $105 per share in cash, without interest thereon and net of any required tax withholding.

  • GlobeNewswire4 days ago

    Sanofi: Disclosure of trading in own shares

    Disclosure of trading in own shares This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are ...

  • Globe Newswire4 days ago

    Sanofi: Disclosure of trading in own shares

    Attachments:

  • Why 2018 Could Be An Explosive Year For Biotech Mergers
    Investor's Business Daily7 days ago

    Why 2018 Could Be An Explosive Year For Biotech Mergers

    This year could be big for biotech mergers after Celgene and Sanofi, in a few days, spent $25 billion for three companies.

  • Forbes7 days ago

    Healthcare Stocks In The News Last Week

    believe that many investors under-appreciate Sanofi’s non-diabetes businesses and think that the strength from the rest of the company will provide plenty of opportunity for upside, including the new acquisitions and pipeline. The recent slide in shares makes SNY an attractive purchase in our eyes.

  • Could Novavax, Inc. Be a Millionaire-Maker Stock?
    Motley Fool8 days ago

    Could Novavax, Inc. Be a Millionaire-Maker Stock?

    Novavax is hot right now -- but just how much hotter could this biotech stock get?

  • The Zacks Analyst Blog Highlights: ExxonMobil, Caterpillar, Union Pacific, Alexion and Sanofi
    Zacks9 days ago

    The Zacks Analyst Blog Highlights: ExxonMobil, Caterpillar, Union Pacific, Alexion and Sanofi

    The Zacks Analyst Blog Highlights: ExxonMobil, Caterpillar, Union Pacific, Alexion and Sanofi

  • Reuters - UK Focus9 days ago

    Oxford BioMedica wins second $100 mln gene therapy contract

    Britain's Oxford BioMedica (LSE: OXB.L - news) has won a second $100 million contract to supply gene therapy material, this time from Bioverativ, which agreed last month to be acquired by Sanofi (LSE: 0O59.L - news) for $11.6 billion. Oxford Bio said on Thursday it would receive $5 million upfront and would be eligible for various milestone payments, potentially worth in excess of $100 million, plus royalties on sales of haemophilia therapies that Bioverativ is developing. The deal follows a similar $100 million contract last year to supply lentiviral vectors, which are used to deliver DNA (Frankfurt: 24D.F - news) into cells, for Novartis (IOB: 0QLR.IL - news) 's pioneering leukaemia treatment Kymriah.

  • GlobeNewswire11 days ago

    Sanofi : Information concerning the total number of voting rights and shares

    Information concerning the total number of voting rights and shares This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement ...

  • Alnylam Pharmaceuticals Starts the Wait for Approval
    Motley Fool11 days ago

    Alnylam Pharmaceuticals Starts the Wait for Approval

    Following solid data from the Apollo phase 3 trial, an approval of patisiran seems likely.

  • GlobeNewswire11 days ago

    Sanofi: Disclosure of trading in own shares

    Disclosure of trading in own shares This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are ...

  • Globe Newswire11 days ago

    Sanofi: Disclosure of trading in own shares

    Attachments:

  • Reuters15 days ago

    L'Oreal ready to buy Nestle stake in cosmetics leader

    L'Oreal signalled its readiness to buy Nestle's 23 percent stake in the world's biggest cosmetics firm on Friday, which along with strong results lifted the French company's shares. L'Oreal said it could finance a purchase of the holding, which is now worth around 22.3 billion euros ($27.4 billion), with cash, by selling its stake in French pharmaceutical group Sanofi or through borrowing. "If Nestle one day wants to sell, we are ready," Chairman and Chief Executive Jean-Paul Agon said after L'Oreal released fourth-quarter earnings.

  • Reuters15 days ago

    L'Oreal ready to buy shareholder Nestle's stake in the firm: CEO

    L'Oreal (OREP.PA) stands ready to buy Nestle's (NESN.S) 23 percent stake in the firm should its Swiss shareholder choose to sell, and it could finance a purchase through cash, by selling its Sanofi (SASY.PA) stake or by borrowing, L'Oreal's CEO said. "If Nestle one day wants to sell, we are ready," L'Oreal's Chairman and Chief Executive Jean-Paul Agon told a news conference on Friday, after the cosmetics company released its fourth-quarter earnings on Thursday.

  • Reuters15 days ago

    L'Oreal ready to buy shareholder Nestle's stake in the firm - CEO

    L'Oreal (OREP.PA) stands ready to buy Nestle's (NESN.S) 23 percent stake in the firm should its Swiss shareholder choose to sell, and it could finance a purchase through cash, by selling its Sanofi (SASY.PA) stake or by borrowing, L'Oreal's CEO said. "If Nestle one day wants to sell, we are ready," L'Oreal's Chairman and Chief Executive Jean-Paul Agon told a news conference on Friday, after the cosmetics company released its fourth-quarter earnings on Thursday.

  • Regeneron (REGN) Q4 Earnings & Revenues Top, Eylea Sales Grow
    Zacks15 days ago

    Regeneron (REGN) Q4 Earnings & Revenues Top, Eylea Sales Grow

    Regeneron (REGN) fourth-quarter results were encouraging as the company topped both earnings and sales estimates on the back of Eylea sales.

  • GlobeNewswire16 days ago

    Sanofi Commences Tender Offer for Acquisition of Bioverativ Inc.

      Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi Commences Tender Offer for Acquisition of Bioverativ Inc. Paris - February 8, 2018 - Sanofi announced today that on February 7, 2018 it ...

  • Globe Newswire16 days ago

    Sanofi Commences Tender Offer for Acquisition of Bioverativ Inc.

    February 8, 2018 - Sanofi announced today that on February 7, 2018 it commenced a tender offer (the "Offer") to acquire all of the outstanding shares of common stock of Bioverativ, Inc. ("Bioverativ") for $105 per share in cash (the "Offer Price"), without interest thereon and net of any required tax withholding. The Offer is being made pursuant to the Agreement and Plan of Merger, dated as of January 21, 2018 (as it may be amended from time to time, the "Merger Agreement"), by and among Bioverativ, Sanofi and Blink Acquisition Corp., a Delaware corporation and an indirect, wholly-owned subsidiary of Sanofi ("Purchaser").

  • Sanofi, Regeneron Dip As Eczema Drug Dupixent Lags In Europe
    Investor's Business Daily16 days ago

    Sanofi, Regeneron Dip As Eczema Drug Dupixent Lags In Europe

    Sanofi and Regeneron's Dupixent is off to a strong start in the U.S., but revenue from the eczema drug lagged in Europe.

  • MarketWatch16 days ago

    European stocks end with gains, halting 7-day skid

    European stocks close with firm gains on Wednesday, breaking a seven-day losing run after Wall Street managed to bounce higher in the prior day’s volatile session following the biggest global selloff in ...

  • Sanofi (SNY) Q4 2017 Earnings Conference Call Transcript
    Motley Fool16 days ago

    Sanofi (SNY) Q4 2017 Earnings Conference Call Transcript

    SNY earnings call for the period ending December 31, 2017.

  • Sanofi's Deal Desperation Now Looks Even Worse
    Bloomberg16 days ago

    Sanofi's Deal Desperation Now Looks Even Worse

    Weak earnings show it needs help, but it overpaid for M&A right at the market top.

  • Sanofi (SNY) Q4 Earnings Lag on Weak Diabetes/Vaccines Sales
    Zacks17 days ago

    Sanofi (SNY) Q4 Earnings Lag on Weak Diabetes/Vaccines Sales

    Sanofi misses estimates for both earnings and sales in the fourth quarter hurt by continued weakness in the Diabetes franchise and lower vaccine sales. Sanofi looks to return to growth in 2018.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes